Sept 30 (Reuters) – Regeneron Pharmaceuticals Inc
said a combination therapy containing its flagship eye drug,
Eylea, was inferior to Eylea alone in a mid-stage trial
involving patients with wet…
The post UPDATE 1-Regeneron’s Eylea combination therapy fails mid-stage study appeared first on NASDAQ.